Drugs / DC-806
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06092931 | Oct → Nov 2023 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06045000 | Sep → Oct 2023 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05994807 | Aug → Sep 2023 | — | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06808815 | Sep 2021 → Aug 2022 | psoriasis | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05896527 | May 2023 → Mar 2024 | psoriasis | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC-806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05896527 ↗ |
| Route | Oral | “administered orally” NCT05896527 ↗ |